# Clinical Trial Landscape: 07_pancreatic_kras_g12d

*Generated: 2026-01-05 18:31:00*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 42 | ████████ 42.0% |
| Phase 1/Phase 2 | 17 | ███ 17.0% |
| Unknown | 13 | ██ 13.0% |
| Phase 2 | 13 | ██ 13.0% |
| Not Applicable | 9 | █ 9.0% |
| Phase 3 | 2 |  2.0% |
| Early Phase 1 | 2 |  2.0% |
| Phase 2/Phase 3 | 1 |  1.0% |
| Phase 4 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 94 (94.0%)
- **Not yet recruiting**: 4 (4.0%)
- **Enrolling by invitation**: 2 (2.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| City of Hope Medical Center | 5 |
| National Cancer Institute (NCI) | 4 |
| Pfizer | 4 |
| M.D. Anderson Cancer Center | 3 |
| Sidney Kimmel Comprehensive Cancer Center at Johns | 3 |
| Astellas Pharma Inc | 3 |
| Revolution Medicines, Inc. | 3 |
| University of Nebraska | 2 |
| University of Chicago | 2 |
| University of Colorado, Denver | 2 |
| Novartis Pharmaceuticals | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Eli Lilly and Company | 2 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Gemcitabine | 15 |
| Cetuximab | 11 |
| Oxaliplatin | 9 |
| Irinotecan | 8 |
| Pembrolizumab | 8 |
| Leucovorin | 7 |
| Carboplatin | 6 |
| Biospecimen Collection | 6 |
| Fluorouracil | 5 |
| Cisplatin | 5 |
| Pemetrexed | 5 |
| Computed Tomography | 5 |
| Nab-paclitaxel | 5 |
| RMC-6236 | 5 |
| RMC-9805 | 4 |
| TSN1611 | 4 |
| Pancreatectomy | 3 |
| nab-paclitaxel | 3 |
| FOLFIRI | 3 |
| Paclitaxel | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 14 |
| France | 11 |
| Canada | 11 |
| Australia | 10 |
| Italy | 9 |
| United Kingdom | 7 |
| Japan | 7 |
| Belgium | 6 |
| Israel | 5 |
| Taiwan | 5 |
| China | 5 |
| Germany | 5 |
| Netherlands | 4 |
| Puerto Rico | 4 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12D | manual | 1.0 |
| KRASG12D | manual | 0.9 |
| KRAS-G12D | manual | 0.9 |
| pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic ductal adenocarcinoma | llm | 0.9 |
| KRAS G12D PDAC | llm | 0.9 |
| pancreatic ductal adenocarcinoma | llm | 0.8 |
| PDAC | llm | 0.8 |
| KRAS p.G12D | llm | 0.9 |
| KRASp.G12D | llm | 0.8 |
| KRAS-p.G12D | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07282912](https://clinicaltrials.gov/study/NCT07282912) | Phase 2 | Not yet recruiting | Yale University | Phase II Prospective, Open Label Ra... |
| [NCT07202247](https://clinicaltrials.gov/study/NCT07202247) | Phase 2 | Recruiting | City of Hope Medical... | A Phase II Randomized Study of Inte... |
| [NCT06821997](https://clinicaltrials.gov/study/NCT06821997) | Phase 2 | Recruiting | Roswell Park Cancer ... | A Phase 2 Clinical Trial of Nalirif... |
| [NCT07033689](https://clinicaltrials.gov/study/NCT07033689) | Early Phase 1 | Not yet recruiting | SONIRE Therapeutics ... | Open-label, Non-randomized, Single-... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07270237](https://clinicaltrials.gov/study/NCT07270237) | Not Applicable | Recruiting | Memorial Sloan Kette... | Development and Evaluation of Ultra... |
| [NCT06790602](https://clinicaltrials.gov/study/NCT06790602) | Phase 2 | Not yet recruiting | University of Califo... | A Single-arm, Open-label, Phase II ... |
| [NCT07024615](https://clinicaltrials.gov/study/NCT07024615) | Phase 1 | Recruiting | Astellas Pharma Glob... | A Phase 1b Study of Neoadjuvant ASP... |
| [NCT06989437](https://clinicaltrials.gov/study/NCT06989437) | Phase 2/Phase 3 | Recruiting | Pfizer | A Phase 2b/3, Randomized, Double-Bl... |
| [NCT07043270](https://clinicaltrials.gov/study/NCT07043270) | Phase 2 | Recruiting | Dartmouth-Hitchcock ... | 24BRO681 : Neoadjuvant Therapy With... |
| [NCT07141706](https://clinicaltrials.gov/study/NCT07141706) | Phase 1 | Recruiting | DualityBio Inc. | A Phase 1a/1b, Multicenter, Open-La... |
| [NCT07207707](https://clinicaltrials.gov/study/NCT07207707) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1a, Open-label, Multicenter... |
| [NCT07047807](https://clinicaltrials.gov/study/NCT07047807) | Not Applicable | Not yet recruiting | Massachusetts Genera... | PDAC-PATHWAYS: A Digital Informatio... |
| [NCT07145255](https://clinicaltrials.gov/study/NCT07145255) | Phase 1/Phase 2 | Recruiting | MBrace Therapeutics | A Multicenter, Open-label Phase 1/2... |
| [NCT06906562](https://clinicaltrials.gov/study/NCT06906562) | Phase 2 | Recruiting | Sameek Roychowdhury | A Phase II Nationwide, Fully Decent... |
| [NCT06910657](https://clinicaltrials.gov/study/NCT06910657) | Phase 1 | Recruiting | ViroMissile, Inc. | A First-in-human, Phase I, Multi-ce... |
| [NCT06984562](https://clinicaltrials.gov/study/NCT06984562) | Not Applicable | Recruiting | Fox Chase Cancer Cen... | Adaptive Radiation for Locally Adva... |
| [NCT07090499](https://clinicaltrials.gov/study/NCT07090499) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-label Study to Inves... |
| [NCT07120295](https://clinicaltrials.gov/study/NCT07120295) | Phase 4 | Recruiting | University of Colora... | Prospective Multicenter Clinical Pe... |
| [NCT07118176](https://clinicaltrials.gov/study/NCT07118176) | Phase 1 | Recruiting | Jonsson Comprehensiv... | PET Imaging Study of 68Ga-FAPI-46 B... |
| [NCT07021066](https://clinicaltrials.gov/study/NCT07021066) | Phase 1 | Recruiting | SystImmune Inc. | A Phase 1 Open-Label Study to Evalu... |
| [NCT07094204](https://clinicaltrials.gov/study/NCT07094204) | Phase 1 | Recruiting | Astellas Pharma Inc | A Phase 1 Study of ASP5834 in Parti... |
| [NCT06411691](https://clinicaltrials.gov/study/NCT06411691) | Phase 1 | Recruiting | Sidney Kimmel Compre... | Pooled Mutant KRAS-Targeted Long Pe... |
| [NCT06630325](https://clinicaltrials.gov/study/NCT06630325) | Phase 2 | Recruiting | OHSU Knight Cancer I... | Serial Measurements of Molecular an... |
| [NCT07020221](https://clinicaltrials.gov/study/NCT07020221) | Phase 1/Phase 2 | Recruiting | Verastem, Inc. | A Phase 1/2a, Open-label Study of V... |
| [NCT06698458](https://clinicaltrials.gov/study/NCT06698458) | Not Applicable | Recruiting | Alpha Tau Medical LT... | A Study to Assess the Safety of Int... |
| [NCT06995898](https://clinicaltrials.gov/study/NCT06995898) | Not Applicable | Recruiting | National Cancer Inst... | The Vanguard Study: Testing a New W... |
| [NCT06999187](https://clinicaltrials.gov/study/NCT06999187) | Phase 1 | Recruiting | Dren Bio | A Phase 1a/1b, Multicenter, Open-la... |
| [NCT06922591](https://clinicaltrials.gov/study/NCT06922591) | Phase 1/Phase 2 | Recruiting | Tango Therapeutics, ... | A Phase 1/2, Multicenter, Open-Labe... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06747845](https://clinicaltrials.gov/study/NCT06747845) | Phase 2 | Recruiting | Abramson Cancer Cent... | ParpVax2: A Phase II Study Of Maint... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06797336](https://clinicaltrials.gov/study/NCT06797336) | Phase 1 | Recruiting | PAQ Therapeutics, In... | A Phase 1, Open-Label Dose Escalati... |
| [NCT06663072](https://clinicaltrials.gov/study/NCT06663072) | Phase 1 | Recruiting | University of Chicag... | A Phase I Study of Fulvestrant in C... |
| [NCT06271291](https://clinicaltrials.gov/study/NCT06271291) | N/A | Recruiting | Mayo Clinic | Pancreatic Cancer Detection Consort... |
| [NCT06704724](https://clinicaltrials.gov/study/NCT06704724) | Phase 1 | Recruiting | Pfizer | A PHASE 1 OPEN-LABEL STUDY OF PF-07... |
| [NCT07226154](https://clinicaltrials.gov/study/NCT07226154) | N/A | Recruiting | City of Hope Medical... | An Exosomal miRNA Based Predictive ... |
| [NCT06619587](https://clinicaltrials.gov/study/NCT06619587) | Phase 1 | Recruiting | Genentech, Inc. | A Phase I/II Dose-Escalation and Ex... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06276764](https://clinicaltrials.gov/study/NCT06276764) | N/A | Enrolling by invitation | Adenocyte, LLC | The LINFU® U.S. Registry for the De... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06586515](https://clinicaltrials.gov/study/NCT06586515) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Trial of LY3962673 in... |
| [NCT06158139](https://clinicaltrials.gov/study/NCT06158139) | Phase 1 | Recruiting | UNC Lineberger Compr... | A Phase I Study of Autologous CAR-T... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT07224802](https://clinicaltrials.gov/study/NCT07224802) | N/A | Recruiting | City of Hope Medical... | An Exosome-based Liquid Biopsy Sign... |
| [NCT06360354](https://clinicaltrials.gov/study/NCT06360354) | Phase 1 | Recruiting | Amgen | A Phase 1b Study Evaluating the Saf... |
| [NCT06445062](https://clinicaltrials.gov/study/NCT06445062) | Phase 1/Phase 2 | Recruiting | Revolution Medicines... | A Platform Study of RAS(ON) Inhibit... |
| [NCT06122480](https://clinicaltrials.gov/study/NCT06122480) | Not Applicable | Recruiting | Sidney Kimmel Compre... | Surgical Resection of Synchronous P... |
| [NCT06454383](https://clinicaltrials.gov/study/NCT06454383) | Phase 1 | Recruiting | City of Hope Medical... | A Phase 1b Study of Gemcitabine and... |
| [NCT06048484](https://clinicaltrials.gov/study/NCT06048484) | Phase 2 | Recruiting | Gulam Manji | A Phase 2, Open-Label, Multicenter,... |

*... and 50 more trials (see trials.csv for full list)*
